Maclurin

Maclurin is a C-glucosylated dihydrochalcone flavonoid found in mulberry wood, jackfruit, and gamboge that exerts anti-inflammatory effects primarily by inhibiting caspase-11-mediated non-canonical inflammasome activation. Its anticancer activity involves suppression of cell proliferation and apoptosis induction in prostate, lung, and osteosarcoma cancer cell lines through modulation of oxidative stress pathways.

Origin & History

Maclurin is a natural phenolic compound extracted from the twigs of Morus alba (white mulberry) and the fruit of Garcinia mangostana (purple mangosteen). It is produced through ethanol extraction, focusing on its bioactive properties.

Historical & Cultural Context

There are no specific historical or traditional uses detailed for maclurin itself. However, plants like Morus alba and Garcinia mangostana, from which it is derived, have been used in traditional medicine, suggesting potential anti-inflammatory applications.

Health Benefits

• May reduce inflammation by inhibiting caspase-11 inflammasome, as shown in a mouse study (PMID: 38330799).
• Demonstrates anti-cancer activity in vitro in prostate, lung, and osteosarcoma cell lines, though without human trials (PMIDs: 30340816, 25630491, 34003554).
• Reduces pro-inflammatory cytokines such as IL-1β and IL-18 in animal models (PMID: 38330799).
• Promotes melanogenesis by upregulating melanogenic enzymes in cells (no human studies).
• Exhibits prooxidant activity in cancer cells, which could contribute to its anti-cancer effects, as observed in vitro.

How It Works

Maclurin inhibits the non-canonical NLRP3 inflammasome pathway by blocking caspase-11 activation, thereby reducing gasdermin D-mediated pyroptosis and downstream release of pro-inflammatory cytokines including IL-1β and IL-18. In cancer cell lines, maclurin modulates reactive oxygen species (ROS) generation, promotes mitochondrial-mediated apoptosis, and suppresses NF-κB signaling to reduce tumor cell survival. It also inhibits inflammatory mediators such as COX-2 and iNOS, contributing to its broader anti-inflammatory profile observed in preclinical models.

Scientific Research

No human clinical trials or meta-analyses have been conducted on maclurin. All current evidence comes from preclinical in vitro and in vivo studies (PMIDs: 38330799, 30340816, 25630491, 34003554).

Clinical Summary

Maclurin's evidence base is entirely preclinical, comprising in vitro cell studies and at least one in vivo mouse model (PMID: 38330799), with no human clinical trials published to date. The mouse study demonstrated measurable reduction of caspase-11-dependent inflammation, while separate in vitro studies in prostate (LNCaP, PC-3), lung, and osteosarcoma cell lines showed dose-dependent antiproliferative and pro-apoptotic effects (PMIDs: 30340816, 25630491, 34003554). Quantified outcomes in cell studies include significant reductions in cell viability at micromolar concentrations, though precise IC50 values and in vivo pharmacokinetic data remain incompletely characterized. The current evidence is insufficient to support clinical recommendations, and human bioavailability, effective dosing, and long-term safety have not been established.

Nutritional Profile

Maclurin (3,4,2',4'-tetrahydroxybenzophenone) is a naturally occurring polyphenolic compound (benzophenone class) isolated primarily from Maclura pomifera (Osage orange), Garcinia species, and mulberry heartwood. It is not a macronutrient or micronutrient itself but a secondary plant metabolite with a molecular weight of 246.22 g/mol. As a pure bioactive compound, it contains no protein, fat, fiber, or caloric value in isolation. Its key structural feature is four hydroxyl groups on two aromatic rings, conferring potent radical-scavenging capacity (DPPH IC50 values reported in the low micromolar range, approximately 10–50 µM depending on assay conditions). Bioavailability data in humans is largely absent; however, its polyphenolic structure suggests moderate intestinal absorption with likely phase II conjugation (glucuronidation, sulfation) in hepatic and intestinal metabolism, similar to other small benzophenone polyphenols. Oral bioavailability is expected to be limited by first-pass metabolism, as is typical for this compound class. No established dietary reference intake or therapeutic dosage has been defined for humans.

Preparation & Dosage

No clinically studied dosage ranges are available for maclurin, as all evidence is preclinical. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Maclurin pairs well with Quercetin, as both inhibit overlapping pro-inflammatory pathways (NF-κB and NLRP3/caspase-11 inflammasome suppression), producing additive anti-inflammatory effects while quercetin's inhibition of P-glycoprotein efflux transporters may modestly enhance maclurin's cellular retention. Pipeine (from black pepper) is a logical co-ingredient given its well-documented inhibition of CYP3A4 and glucuronosyltransferases (UGTs), which could reduce maclurin's phase II conjugation and increase its systemic bioavailability, a mechanism validated for structurally similar polyphenols like curcumin. Additionally, Resveratrol complements maclurin's anti-cancer activity in prostate and lung cell lines through complementary mechanisms — maclurin acts via caspase-dependent apoptotic pathways while resveratrol modulates SIRT1/p53 and PI3K/Akt signaling — creating multi-target coverage without known antagonistic interactions at physiologically relevant concentrations.

Safety & Interactions

No human safety data, clinical adverse event profiles, or established tolerable upper intake levels exist for maclurin, as it has not been studied in human trials. Because maclurin modulates NF-κB and COX-2 pathways, theoretical interactions with NSAIDs, corticosteroids, or anticoagulants such as warfarin cannot be ruled out and warrant caution. Pregnancy and lactation safety is entirely unknown, and use should be avoided in these populations until evidence is available. Individuals on immunosuppressive therapy or chemotherapy agents should consult a healthcare provider before using any maclurin-containing supplement, given its observed effects on apoptotic and inflammatory pathways.